Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors

Published:2021-01-13 Issue:8 Volume:10 Page:940-949
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Shapiro Geoffrey I.¹,O'Mara Edward²,Laskin Oscar L.²,Gao Lan²,Baird John D.²,Spiegel Robert J.²,Kaushik Diksha²,Weetall Marla²,Colacino Joseph²,O'Keefe Kylie²,Branstrom Arthur²,Goodwin Elizabeth²,Infante Jeffrey³,Bedard Philippe L.⁴,Kong Ronald²

Affiliation:

1. Dana‐Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA

2. PTC Therapeutics, Inc. South Plainfield New Jersey USA

3. Sarah Cannon Research Institute and Tennessee Oncology PLLC Nashville Tennessee USA

4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine University of Toronto Toronto Ontario Canada

Funder

PTC Therapeutics

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.904

Reference22 articles.

1. Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?

2. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

3. The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma